1. female participants who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

1. female participants who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

female participants who are pregnant or nursing participation in a clinical trial with another investigational drug for covid-19 disease anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

female participants who are pregnant or nursing participation in a clinical trial with another investigational drug for covid-19 disease anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

1. female participants who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

1. female participants who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

1. female subjects who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies -

1. female subjects who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies -